EXACT: Rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease

International Journal of Clinical Practice

Volumn 61, Issue 6, 2007, Pages 886-895

  Gauthier, S ^a   Juby, A ^b   Rehel, B ^c   Schecter, R ^c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DONEPEZIL; GALANTAMINE; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; RIVASTIGMINE;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ANXIETY; APATHY; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CANADA; CAREGIVER BURDEN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MOOD DISORDER; MULTICENTER STUDY; OPEN STUDY; OUTPATIENT; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; AFFECT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ATTENTION; BEHAVIOR; CANADA; CAREGIVERS; CHOLINESTERASE INHIBITORS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PHENYLCARBAMATES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34248341709     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01387.x     Document Type: Article

References (32)

1. Gauthier S, Keren R, Juby A et al. EXACT: Exelon Therapy to ACT on the Four As of Alzheimer's Disease. Poster presented at the Canadian Colloquium on Dementia, Ottawa, October 2005.
2. Perry EK, Perry RH, Blessed G et al. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978 4 : 273 7.
3. Weinstock M. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer's disease. CNS Drugs 1999 12 : 307 23.
4. Giacobini E. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease Drugs Aging 2001 18 : 891 8.
5. Geula C, Mesulam MM. Cholinergic systems and related neuropathological predilection patters in Alzheimer disease. In : Bick KL, Katzman R, Terry RD, eds. Alzheimer Disease. New York : Raven Press Ltd, 1994 : 263 91.
6. Bouchard RW, Rossor M. Typical clinical features. In : Gauthier S, ed. Clinical Diagnosis and Management of Alzheimer's Disease. London : Martin Dunitz Ltd., 1996 : 35 51.
7. Perry RJ, Hodges JR. Attention and executive deficits in Alzheimer's disease. A critical review. Brain 1999 122 (Pt 3 383 404.
8. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc 1996 44 : 1078 81.
9. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996 46 : 130 5.
10. Levy ML, Cummings JL, Fairbanks LA et al. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996 153 : 1438 43.
11. Dura JR, Stukenberg KW, Kiecolt-Glaser JK. Anxiety and depressive disorders in adult children caring for demented parents. Psychol Aging 1991 6 : 467 73.
12. Hinchcliffe AC, Hyman IL, Blizard B, Livingston G. Behavioural complications of dementia - can they be treated Int Geriatr Psychiatry 1995 10 : 839 47.
13. Cummings JL. Theories behind existing scales for rating behavior in dementia. Int Psychogeriatr 1996 8 (Suppl. 3 293 300.
14. Teri L, Logsdon RG. Methodologic issues regarding outcome measures for clinical drug trials of psychiatric complications in dementia. J Geriatr Psychiatry Neurol 1995 8 (Suppl. 1 S8 17.
15. Grossberg GT. The ABC of Alzheimer's disease: behavioural symptoms and their treatment. Int Psychogeriatr 2002 14 (Suppl. 1 27 49.
16. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease for the ENA 713 B352 Study Group. Int J Geriatric Psychopharmacol 1998 1 : 55 65.
17. Rösler M, Retz W, Retz-Junginger P, Dennler HJ. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol 1998 11 : 211 6.
18. Rösler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999 318 : 633 8. Erratum in : BMJ 2001 322 : 1456.
19. Bullock R, Touchon J, Bergman H et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005 21 : 1317 27.
20. Rösler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl 2002 127 : 20 36.
21. Gauthier S, Juby A, Morelli L et al. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Curr Med Res Opin 2006 22 : 2251 65.
22. Bullock R, Moulias R, Steinwachs K-C et al. Effects of rivastigmine on behavioural symptoms in nursing home patients with Alzheimer's disease. Int Psychogeriatr 2001 13 (Suppl. 2 248 [abstract].
23. Cummings J, Anand R, Koumaras B et al. Rivastigmine provides behavioural benefits to Alzheimer's disease patients residing in a nursing home: findings from a 26-week trial. Neurology 2000 54 (Suppl. 3 A468 [abstract].
24. Etemad B. Behavioral and cognitive benefits of rivastigmine in nursing home patients with Alzheimer's disease and related dementias: a 26-week follow-up. Int Psychogeriatr 2001 13 (Suppl. 246 [abstract].
25. Messina J, Koumaras B, Sohn H et al. Treatment with Rivastigmine Reduces the Need for Psychotropic Medications in Patients with Alzheimer's Disease Residing in Long-term Care Facilities. Poster presented at the 3rd International Meeting of the College of Psychiatric Neurological Pharmacists, Washington, DC, 2001.
26. Farlow M, Anand R, Messina J Jr. et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000 44 : 236 41.
27. Alzheimer's Society of Canada. Alzheimer's Disease Fact Sheet. http://www.alzheimer.ca (accessed June 2006).
28. Wesnes KA, McKeith I, Edgar C et al. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005 65 : 1654 6.
29. Wesnes KA, McKeith IG, Ferrara R et al. Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 2002 13 : 183 92.
30. Eskander MF, Nagykery NG, Leung EY et al. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain Res 2005 1060 : 144 52.
31. Darvesh S, Hopkins DA. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. J Comp Neurol 2003 463 : 25 43.
32. Aupperle PM, Koumaras B, Chen M et al. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Curr Med Res Opin 2004 20 : 1605 12.